Clinical research of repeat transurethral resection for treating stage T1 of non-muscle invasive bladder cancer
10.3969/j.issn.1671-8348.2016.12.016
- VernacularTitle:经尿道二次电切治疗 T1期非肌层浸润性膀胱癌的临床研究
- Author:
Yuan LI
;
Peng XIAN
;
Nan LIU
;
Hong LUO
;
Jun LI
;
Junyong DAI
;
Yanping SONG
- Publication Type:Journal Article
- Keywords:
bladder tumor;
repeat transurethral resection;
transurethral resection of bladder tumor
- From:
Chongqing Medicine
2016;45(12):1635-1637
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the significance and safety of repeat transurethral resection(Re‐TUR) for treating stage T1 of non‐muscle invasive bladder cancer .Methods The clinical data were retrospectively analyzed on 41 cases of stage T1 of non‐muscle invasive bladder cancer in this department of our hospital from January 2013 to November 2014 .All cases underwent Re‐TUR at 4-6 weeks after primary surgery .Among them ,33 cases were male and 8 cases were female ,24 cases were single tumor and 17 cases were multiple tumors at first operation .The maximal tumor diameter was ≥ 3 cm in 13 cases and <3 cm in 28 cases . The first treatment was transurethral resection of bladder tumor(TURB‐t) .The pathological report was the stage T1 of urothelium cancer .Results All 41 cases were completed the operation smoothly ,and no serious complication occurred .In the postoperative pathological examination ,7 cases(17 .07% ) had tumor residue or tumor recurrence ,among them ,3 case had residue f tumor base and 4 cases were new onset tumor;the pathological grade at Re‐TUR in 1 case was increased from G2 to G3 .The follow up lasted for 3―27 months(average 13 .2 months) ,9 cases relapsed ,3 cases (42 .86% ,3/7) were positive at Re‐TUR and 6 cases(17 .65% , 6/34) were negative at Re‐TUR .Conclusion Re‐TUR for treating stage T1 of non‐muscle invasive bladder cancer is safe and feasi‐ble ,its significance to pick out high‐risk patient for conducting further active treatment ,which may have certain effect for reducing the recurrence rate of non‐muscle invasive bladder cancer .
